Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of lenvatinib in unresectable biliary tract cancer after gemcitabine-based chemotherapy
jRCT2080222988Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in biliary cancer, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA) and 2 more, sponsored by Eisai Co., Ltd. Started Oct 2015; status: completed.
02
Drugs
lenvatinib
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on jRCT2080222988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222988.